Lilly Was Already Pharma’s Biggest Company. Now It’s Doing Deals to Match

Eli Lilly, already the largest pharmaceutical company globally with a market capitalization nearing $1 trillion, has embarked on an unprecedented M&A and licensing spree in 2026, spending over $20 billion—and up to $25 billion—on deals that represent more than half of the acquisitions made by the top 12 pharmas this year

The company has announced at least 10 major acquisitions in 2026, including high‑value takeovers such as up to $7.8 billion for Centessa Pharmaceuticals (sleep/narcolepsy), up to $7 billion for Kelonia Therapeutics (cancer), and up to $3.8 billion for three vaccine developers (Curevo, LimmaTech Biologics, Vaccine Company), along with a wave of licensing and AI‑driven discovery collaborations

Flush with cash from its GLP‑1 obesity and diabetes drugs like Mounjaro and Zepbound, Lilly is using its windfall to diversify its pipeline beyond obesity into oncology, cardiovascular, neuroscience, immunology, and infectious diseases, while pursuing mostly preclinical and early‑stage assets rather than just late‑stage blockbusters to fill patent‑expiry gaps

Analysts note that Lilly is now “buying the future” by stacking bets on early‑stage and platform technologies, contrasting with other big pharma firms that are still focused on later‑stage acquisitions to plug near‑term revenue holes, which underscores how Lilly’s deals are finally matching its status as the world’s most valuable pharma company